Vaxcyte, Inc.

We are a clinical-stage vaccine innovation company focused on developing vaccines to protect against bacterial diseases. We use our XpressCF™ cell-free protein synthesis platform to produce complex vaccines. This system aims to create high-fidelity vaccines with enhanced immunological benefits, which differs from conventional cell-based methods. The global vaccine market is large, durable, and growing, driven by routine pediatric vaccinations and increased adult vaccination due to new vaccines, expanded age recommendations, and international adoption. We target areas with significant unmet medical needs, including vaccines that offer broader protection against current and historical strains, and novel vaccines for pathogens without approved treatments. Our selection criteria for target disease areas and vaccine candidates include significant unmet medical need, clear commercial opportunity, efficient market adoption, acceptable biological risk, and established or acceptable clinical pathways. We are using our scalable cell-free protein synthesis platform to develop conjugate and protein vaccine candidates for adult and pediatric indications. Our pipeline includes PCV (Pneumococcal Conjugate Vaccine) candidates, which we believe are among the broadest-spectrum PCV candidates in development, targeting the approximately $8 billion global pneumococcal vaccine market. Pneumococcal disease (PD) is an infection caused by *Streptococcus pneumoniae* bacteria.